Ryan Bhatt

Ryan Bhatt has investigated the combination and sequencing of BRAF/MEK targeted therapy with immunotherapy in BRAF-mutated malignancies, recognizing that targeted therapy can potentially prime the immune microenvironment to enhance subsequent or concurrent checkpoint blockade. His research has examined the TRILOGY trial of atezolizumab, vemurafenib, and cobimetinib in BRAF V600-mutated advanced melanoma, exploring whether triplet IO plus BRAF/MEK overcomes resistance compared to BRAF/MEK alone. He has studied mechanisms by which BRAF/MEK inhibition alters T cell infiltration, MHC class I expression, and immunosuppressive cell populations in BRAF-mutated tumors, providing mechanistic rationale for combination with anti-PD-1 therapy. His translational work on sequencing versus concurrent administration of BRAF/MEK plus immunotherapy has informed clinical strategy development for BRAF-mutated melanoma and NSCLC.